Alison Schecter

CMO at Retension Pharmaceuticals

Speaker

Alison has broad scientific/medical expertise with leadership success in both large pharma (Novartis, J&J, Sanofi Genzyme) and biotech (Mineralys Therapeutics, Axcella Therapeutics, Selecta Biosciences) in translating basic scientific mechanism(s) into transformative medical breakthroughs and drug development programs across medical specialties, focusing on Rare, Autoimmune, Cardiovascular, Neurology, and Renal as well as MASH/Obesity. Track record of executing to reach key milestones/value inflection points with creation of high-performance teams. Creation and implementation of novel systems biology/AI technology platforms. Extensive Regulatory interactions (FDA/EMA/MHRA/PDMA) and demonstrated ability to obtain new BLA product approvals for the 1st in class enzyme replacement therapy for Niemann-Pick A/B and B, (olipudase alpha, Xempozymeâ), as well for Adynovateâ, a next gen FVIII replacement therapy for Hemophilia A. A creative and strategic thinker, specializing in bringing innovation to create novel hypotheses, and transforming concepts, through out of the box clinical/regulatory/AI based development strategies, to value based inflection points. Track record of raising capital to facilitate approvable medicines for unmet medical needs.